Psoriasis patients’ willingness to accept side-effect risks for improved treatment efficacy

References

• Melnikova I. Psoriasis market. Nat Rev Drug Discov. 2009;8:767–8
   PubMed Web of Science ®Google Scholar
• Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58:826–50
   PubMed Web of Science ®Google Scholar
• Kimball AB, Sundaram M, Samuelson T, et al. Characteristics of psoriasis patients with self-assessed limited disease control despite physician-assessed clear or minimal skin disease. J Am Acad Dermatol. 2013;68:AB194. Available from https://www.aad.org/File%20Library/Global%20navigation/Meetings%20and%20Events/AM%202013/JAAD-Poster-Abstracts-AAD-71st-Annual-Meeting.pdf. Accessed April 2, 2015
   Google Scholar
• Ashcroft DM, Seston E, Griffiths CE. Trade-offs between the benefits and risks of drug treatment for psoriasis: a discrete choice experiment with U.K. dermatologists. Br J Dermatol. 2006;155:1236–41
   PubMed Web of Science ®Google Scholar
• Seston EM, Ashcroft DM, Griffiths CE. Balancing the benefits and risks of drug treatment: a stated-preference, discrete choice experiment with patients with psoriasis. Arch Dermatol. 2007;143:1175–9
   PubMed Web of Science ®Google Scholar
• Bryan S, Buxton M, Sheldon R, et al. Magnetic resonance imaging for the investigation of knee injuries: an investigation of preferences. Health Econ. 1998;7:595–603
   PubMed Web of Science ®Google Scholar
• Gan TJ, Lubarsky DA, Flood EM, et al. Patient preferences for acute pain treatment. Br J Anaesth. 2004;92:681–8
   PubMed Web of Science ®Google Scholar
• Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769–79
   PubMed Web of Science ®Google Scholar
• Ryan M, Farrar S. Using conjoint analysis to elicit preferences for health care. BMJ. 2000;320:1530–3
   PubMed Web of Science ®Google Scholar
• Ryan M, Scott DA, Reeves C, et al. Eliciting public preferences for healthcare: a systematic review of techniques. Health Technol Assess. 2001;5:1–186
   PubMedGoogle Scholar
• Hensher DA, Rose JM, Greene WH. Applied choice analysis. Cambridge: Cambridge University Press, 2005
   Google Scholar
• Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health - a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403–13
   PubMed Web of Science ®Google Scholar
• Dey A. Orthogonal fractional factorial designs. New York: Halstead Press, 1985
   Google Scholar
• Huber J, Zwerina K. The importance of utility balance in efficient choice designs. J Mark Res. 1996;33:307–17
   Web of Science ®Google Scholar
• Kanninen B. Optimal design for multinomial choice experiments. J Mark Res. 2002;39:214–27
   Web of Science ®Google Scholar
• Hauber AB, Gonzalez JM, Schenkel B, et al. The value to patients of reducing lesion severity in plaque psoriasis. J Dermatolog Treat. 2011;22:266–75
   PubMed Web of Science ®Google Scholar
• Burmester GR, Panaccione R, Gordon KB, et al. Adalimumab: long-term safety in 23,458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn’s disease. Ann Rheum Dis. 2013;72:517–24
   PubMed Web of Science ®Google Scholar
• Opmeer BC, Heydendael VM, deBorgie CA, et al. Patients with moderate-to-severe plaque psoriasis preferred oral therapies to phototherapies: a preference assessment based on clinical scenarios with trade-off questions. J Clin Epidemiol. 2007;60:696–703
   PubMed Web of Science ®Google Scholar
• Fraenkel L, Bogardus ST, Concato J, et al. Patient preferences for treatment of rheumatoid arthritis. Ann Rheum Dis. 2004;63:1372–8
   PubMed Web of Science ®Google Scholar
• Lecluse LL, Tutein Nolthenius JL, Bos JD, et al. Patient preferences and satisfaction with systemic therapies for psoriasis: an area to be explored. Br J Dermatol. 2009;160:1340–3
   PubMed Web of Science ®Google Scholar
• Umar N, Litaker D, Schaarschmidt ML, et al. Outcomes associated with matching patients' treatment preferences to physicians' recommendations: study methodology. BMC Health Serv Res. 2012;12:1
   PubMed Web of Science ®Google Scholar
• Breckenridge A. Patient opinions and preferences in drug development and regulatory decision making. Drug Discov Today Technol. 2012;8:e11–14
   Google Scholar
• European Medicines Agency. Road map to 2015: The European Medicines Agency's contribution to science, medicines, health. Available from http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/01/WC500101373.pdf. Accessed April 2, 2015
   Google Scholar
• Department of Health and Human Services Food and Drug Administration, Center for Devices and Radiological Health, and Center for Biologics Evaluation and Research. Guidance for Industry and Food and Drug Administration Staff – Factors to consider when making benefit-risk determinations in medical device premarket review. Available from http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/UCM296379.pdf. Accessed April 2, 2015
   Google Scholar
• Hauber AB, Johnson FR, Andrews EA. Risk-benefit analysis methods for pharmaceutical decision-making – where are we now? ISPOR Connections. 2006;12:3–5
   Google Scholar
• Weinberg M. Benefit-risk assessment with the patient in mind. iHealth Connections. 2011;1:21–3
   Google Scholar
• Bridges JFP, Kinter ET, Kidane L, et al. Things are looking up since we started listening to patients: trends in the application of conjoint analysis in health 1982–2007. Patient. 2008;1:273–82
   PubMedGoogle Scholar
• Nijsten T, Rolstad T, Feldman SR, et al. Members of the national psoriasis foundation: more extensive disease and better informed about treatment options. Arch Dermatol. 2005;141:19–26
   PubMed Web of Science ®Google Scholar
• Stern RS, Nijsten T, Feldman SR, et al. Psoriasis is common, carries a substantial burden even when not extensive, and is associated with widespread treatment dissatisfaction. J Investig Dermatol Symp Proc. 2004;9:136–9
   PubMed Web of Science ®Google Scholar
• Christophers E, Griffiths CE, Gaitanis G, et al. The unmet treatment need for moderate to severe psoriasis: results of a survey and chart review. J Eur Acad Dermatol Venereol. 2006;20:921–5
   PubMed Web of Science ®Google Scholar
• Nijsten T, Margolis DJ, Feldman SR, et al. Traditional systemic treatments have not fully met the needs of psoriasis patients: results from a national survey. J Am Acad Dermatol. 2005;52:434–44
   PubMed Web of Science ®Google Scholar